Company Description
Polaryx Therapeutics is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”).
Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need.
Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.
Our most advanced product candidate, PLX-200, targets several LSDs and we intend to launch a Phase 2 proof-of-concept basket trial which may enhance PLX-200’s potential to become the standard of care across multiple LSDs.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Alex Yang |
Contact Details
Address: South Tower, 140 E Ridgewood Avenue, Suite 415 Paramus, NJ 07652 United States | |
| Phone | (201) 940-7236 |
| Website | polaryx.com |
Stock Details
| Ticker Symbol | PLYX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002075320 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alex Yang, J.D., LL.M. | Chief Executive Officer and Chair of the Board |
| Lisa L. Bollinger, M.D. | Chief Medical Officer |
| G. Michael Landis, CPA | Chief Financial Officer and Director |
| Andrew O | Chief Investment Officer |
| Mitchel Berger, M.D. | Director |
| Francis A. Braun III, CPA | Director |
| Charles Ryan, J.D., Ph.D. | Director |
| Wuxin (Eddy) Zhu, Ph.D. | Chief Chemistry, Manufacturing and Controls Officer |
| Shrijay Vijayan, Ph.D., MBA | Chief Scientific and Business Development Officer |
| Minsu Kang, Ph.D. | Director of Regulatory and Clinical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 21, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Oct 31, 2025 | C-U | Filing |
| Oct 27, 2025 | C-U | Filing |
| Oct 1, 2025 | C/A | Filing |
| Sep 19, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Sep 3, 2025 | C | Filing |
| Aug 5, 2025 | DRS | [Cover] Draft Registration Statement |